Expert Interview
After ALKS Shows That the Third Time Really Can Be the Charm, Let's discuss the data and Kappa Opioid Receptor Antagonist Class 5
Ticker(s): CERC, ALKSA psychiatrist with experience developing CNS and Depression treatments. A familiarity with the ALKS-5461 and CERC - 501 is essential for this conversation.
What is your background treating depression?
Added By: joe_mccannHow should we think about one positive trial after 2 failed trials for ALKS-5461? Do you think that changing the primary endpoint to an average over the final weeks vs. a single time point was reasonable?
Added By: joe_mccannCan you compare and contrast the CERC-501 compound with the ALKS-5461? There has been comments about CERC-501 being a more selective KOR MOA. Do you think this is true and would be of benefit?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Alkermes' lead product candidate ALKS 5461 did not meet Primary Endpoint in FORWARD-3 and FORWARD-4 Phase 3 studies for Major Depressive Disorder ALKS Occurred on: Jan 21, 2016
- Phase 3 data for third trial of ALKS 5461 due mid-2016 ALKS Occurred On: May 24, 2016
- Phase 3 data from first two trials of ALKS 5461 for Major depressive disorder due 1Q 2016 ALKS Occurred On: Jan 21, 2016
- Data read out from ALKS 5461 FORWARD-4 trial in Treatment Resistant Depression the first of 3 Phase 3 trials currently underway ALKS Occurred On: Jan 21, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
